Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model

Neuron

Volumn 90, Issue 5, 2016, Pages 941-947

  Schoch, Kathleen M ^a   DeVos, Sarah L ^a   Miller, Rebecca L ^a   Chun, Seung J ^b   Norrbom, Michaela ^b   Wozniak, David F ^a   Dawson, Hana N ^c   Bennett, C  Frank ^b   Rigo, Frank ^b   Miller, Timothy M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISOPROTEIN; MAPT PROTEIN; OLIGOMER; TAU PROTEIN; UNCLASSIFIED DRUG; MAPT PROTEIN, HUMAN; MAPT PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; EXON; FEMALE; GENE MUTATION; IN VIVO STUDY; MALE; MAPT GENE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SEIZURE; TAUOPATHY; ANIMAL; BIOLOGICAL MODEL; BRAIN; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; MUTATION; NESTING; PHOSPHORYLATION; RNA SPLICING; SOLUBILITY; TRINUCLEOTIDE REPEAT;

ANIMALS; BRAIN; EXONS; HUMANS; INFUSIONS, INTRAVENTRICULAR; MICE; MODELS, BIOLOGICAL; MUTATION; NESTING BEHAVIOR; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; PROTEIN ISOFORMS; RNA SPLICING; SEIZURES; SOLUBILITY; TAU PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84975519193     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2016.04.042     Document Type: Article

References (37)

1. Adams, S.J., DeTure, M.A., McBride, M., Dickson, D.W., Petrucelli, L., Three repeat isoforms of tau inhibit assembly of four repeat tau filaments. PLoS ONE, 5, 2010, e10810.
2. Andorfer, C., Kress, Y., Espinoza, M., de Silva, R., Tucker, K.L., Barde, Y.A., Duff, K., Davies, P., Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86 (2003), 582–590.
3. Arai, T., Ikeda, K., Akiyama, H., Shikamoto, Y., Tsuchiya, K., Yagishita, S., Beach, T., Rogers, J., Schwab, C., McGeer, P.L., Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 101 (2001), 167–173.
4. Braak, H., Braak, E., Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16 (1995), 271–278, discussion 278–284.
5. Bunker, J.M., Wilson, L., Jordan, M.A., Feinstein, S.C., Modulation of microtubule dynamics by tau in living cells: implications for development and neurodegeneration. Mol. Biol. Cell 15 (2004), 2720–2728.
6. Combs, B., Voss, K., Gamblin, T.C., Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms. Biochemistry 50 (2011), 9446–9456.
7. Cruts, M., Theuns, J., Van Broeckhoven, C., Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 33 (2012), 1340–1344.
8. D'Souza, I., Poorkaj, P., Hong, M., Nochlin, D., Lee, V.M., Bird, T.D., Schellenberg, G.D., Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. USA 96 (1999), 5598–5603.
9. Dawson, H.N., Cantillana, V., Chen, L., Vitek, M.P., The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J. Neurosci. 27 (2007), 9155–9168.
10. Dawson, H.N., Cantillana, V., Jansen, M., Wang, H., Vitek, M.P., Wilcock, D.M., Lynch, J.R., Laskowitz, D.T., Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 169 (2010), 516–531.
11. de Silva, R., Lashley, T., Gibb, G., Hanger, D., Hope, A., Reid, A., Bandopadhyay, R., Utton, M., Strand, C., Jowett, T., et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol. Appl. Neurobiol. 29 (2003), 288–302.
12. Deacon, R.M., Assessing nest building in mice. Nat. Protoc. 1 (2006), 1117–1119.
13. DeVos, S.L., Miller, T.M., Antisense oligonucleotides: treating neurodegeneration at the level of RNA. Neurotherapeutics 10 (2013), 486–497.
14. DeVos, S.L., Miller, T.M., Direct intraventricular delivery of drugs to the rodent central nervous system. J. Vis. Exp., 2013, 10.3791/50326.
15. DeVos, S.L., Goncharoff, D.K., Chen, G., Kebodeaux, C.S., Yamada, K., Stewart, F.R., Schuler, D.R., Maloney, S.E., Wozniak, D.F., Rigo, F., et al. Antisense reduction of tau in adult mice protects against seizures. J. Neurosci. 33 (2013), 12887–12897.
16. Dinkel, P.D., Siddiqua, A., Huynh, H., Shah, M., Margittai, M., Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. Biochemistry 50 (2011), 4330–4336.
17. Ghetti, B., Oblak, A.L., Boeve, B.F., Johnson, K.A., Dickerson, B.C., Goedert, M., Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol. 41 (2015), 24–46.
18. Gheyara, A.L., Ponnusamy, R., Djukic, B., Craft, R.J., Ho, K., Guo, W., Finucane, M.M., Sanchez, P.E., Mucke, L., Tau reduction prevents disease in a mouse model of Dravet syndrome. Ann. Neurol. 76 (2014), 443–456.
19. GlaxoSmithKline (2014). Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy [Online]. Published online August 21, 2014. https://www.clinicaltrials.gov/ct2/show/NCT01153932.
20. Halfmann, R., Lindquist, S., Screening for amyloid aggregation by semi-denaturing detergent-agarose gel electrophoresis. J. Vis. Exp., 2008, 10.3791/838.
21. Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B.I., Geschwind, D.H., Bird, T.D., McKeel, D., Goate, A., et al. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282 (1998), 1914–1917.
22. Hu, J., Matsui, M., Gagnon, K.T., Schwartz, J.C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I., Corey, D.R., Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol. 27 (2009), 478–484.
23. Ionis Pharmaceuticals (2016). A Study to Assess the Efficacy and Safety of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy [Online]. Published online May 6, 2016. Available: https://clinicaltrials.gov/ct2/show/NCT02193074.
24. Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B.C., Christie, M.J., Napier, I.A., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142 (2010), 387–397.
25. Lei, P., Ayton, S., Finkelstein, D.I., Spoerri, L., Ciccotosto, G.D., Wright, D.K., Wong, B.X., Adlard, P.A., Cherny, R.A., Lam, L.Q., et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18 (2012), 291–295.
26. Lu, Q.L., Mann, C.J., Lou, F., Bou-Gharios, G., Morris, G.E., Xue, S.A., Fletcher, S., Partridge, T.A., Wilton, S.D., Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9 (2003), 1009–1014.
27. Ma, Q.L., Zuo, X., Yang, F., Ubeda, O.J., Gant, D.J., Alaverdyan, M., Kiosea, N.C., Nazari, S., Chen, P.P., Nothias, F., et al. Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J. Neurosci. 34 (2014), 7124–7136.
28. Maeda, S., Djukic, B., Taneja, P., Yu, G.Q., Lo, I., Davis, A., Craft, R., Guo, W., Wang, X., Kim, D., et al. Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. EMBO Rep. 17 (2016), 530–551.
29. Miller, V.M., Xia, H., Marrs, G.L., Gouvion, C.M., Lee, G., Davidson, B.L., Paulson, H.L., Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. USA 100 (2003), 7195–7200.
30. Miller, T.M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S.H., Andres, P.L., Mahoney, K., Allred, P., Alexander, K., et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12 (2013), 435–442.
31. Polydoro, M., Acker, C.M., Duff, K., Castillo, P.E., Davies, P., Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J. Neurosci. 29 (2009), 10741–10749.
32. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.Q., Mucke, L., Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007), 750–754.
33. Sanders, D.W., Kaufman, S.K., DeVos, S.L., Sharma, A.M., Mirbaha, H., Li, A., Barker, S.J., Foley, A.C., Thorpe, J.R., Serpell, L.C., et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82 (2014), 1271–1288.
34. Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration. Lancet Neurol. 12 (2013), 609–622.
35. Stoothoff, W., Jones, P.B., Spires-Jones, T.L., Joyner, D., Chhabra, E., Bercury, K., Fan, Z., Xie, H., Bacskai, B., Edd, J., et al. Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J. Neurochem. 111 (2009), 417–427.
36. Torres-Lista, V., Giménez-Llort, L., Impairment of nesting behaviour in 3xTg-AD mice. Behav. Brain Res. 247 (2013), 153–157.
37. von Bergen, M., Barghorn, S., Li, L., Marx, A., Biernat, J., Mandelkow, E.M., Mandelkow, E., Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J. Biol. Chem. 276 (2001), 48165–48174.